Sotagliflozin, a dual SGLT1/SGLT2 glucose transport inhibitor, showed efficacy in Phase 3 trials for Type 1 diabetes (Garg et al., 2017) and in Phase 2 trials for Type 2 diabetes (Rosenstock et al., 2015), and is currently being developed, in collaboration with Sanofi, for both indications. This evidence concerns the gene SLC5A1 and type 2 diabetes mellitus.